U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 50 points on Monday.The Dow traded up 0.69% to 44,294.18 while the NASDAQ fell 0.36% to 19,217.22. The S&P 500 also fell, dropping, 0.04% to 5,993.15.Check This Out: Top 4 Health Care Stocks That May Plunge This QuarterLeading and Lagging SectorsFinancials shares surged by 1.5% on Monday.In trading on Monday, information technology shares fell by 1.4%.Top HeadlineShares of Monday.com Ltd MNDY fell around 16% on Mond ...

SEATTLE, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5550(a)(5) (the "Rule") for continued listing. On November 7 ...

First and only NMPA-approved treatment for patients with CIDP in China  Second VYVGART Hytrulo indication approved in China  November 11, 2024 – 7:30am ET  Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the ...

Nvidia and Meta Platforms led the Nasdaq-100 higher over the last two years.The Nasdaq-100 tracks the performance of the 100 largest non-financial companies listed on the Nasdaq Stock Exchange. Component weighting is adjusted quarterly in March, June, and September, and the entire index is reconstituted annually in December.The Nasdaq-100 is heavily weighted toward the technology sector, a corner of the market where the rise of artificial intelligence (AI) has been particularly impactful. Indeed, Nvidia (NV ...

Core Viewpoint - The JP Morgan Nasdaq Equity Premium Income ETF (JEPQ) offers a combination of a 15% price increase over the past year and a 9.5% dividend yield, but it carries risks related to dividend volatility and limited upside potential [2][5][10] Group 1: ETF Overview - JEPQ is an actively managed ETF that invests in stocks from the Nasdaq-100 index, which consists of the 100 largest stocks on the Nasdaq exchange, primarily in the technology sector [3] - The ETF employs a covered call strategy to generate income, which can benefit from market volatility [4] Group 2: Performance Metrics - Over the past year, JEPQ's price rose by 15%, while the total return, including reinvested dividends, was 27% [5] - The current yield based on the latest dividend payment is 9.5% [5] Group 3: Dividend Characteristics - The monthly dividend has fluctuated between approximately $0.34 and $0.55 per share, indicating significant variability in income [7] - This variability means that the dividend yield may not be reliable for income investors seeking consistent cash flow [6][7] Group 4: Investment Risks - The ETF's reliance on a volatile index can lead to emotional challenges for conservative investors, especially those relying on it for retirement income [8] - Selling covered calls may limit the upside potential of the ETF, as rising investments can be called away, which has been observed in its performance relative to the Nasdaq-100 index [9] - The ETF has not yet established a long performance history, making it uncertain whether it can effectively manage downside risks while providing consistent income [10]

ORINDA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (“MacKenzie” or the “Company”) is pleased to announce that the Company has received approval to list its common stock on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “MKZR”. Trading on Nasdaq is expected to commence with the open of trading on Monday, November 11th. Shareholders are not required to take any action as a result of the uplisting. Trading on Nasdaq will enhance the visibility a ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nvni Group Limited (Nasdaq: NVNI) (“Nuvini”) received a notification letter on November 1, 2024, from Nasdaq’s Listing Qualifications Department, indicating the Company’s minimum bid price per share had been below $1.00 for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the Company’s Nasdaq listing, and shares continue to trade under “NVNI”. Under Nasda ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Points - Biomerica, Inc. has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price requirement of $1.00 per share, extending the deadline to May 5, 2025 [1][2] - The company currently meets all other Nasdaq listing requirements, except for the bid price [2] - To regain compliance, Biomerica's stock must close at or above $1.00 for at least ten consecutive business days before the deadline [3] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products for medical conditions [4] - The company primarily targets gastrointestinal and inflammatory diseases, with multiple diagnostic and therapeutic products in development [4] Product Highlight - The inFoods IBS test assesses patients' immunoreactivity to specific foods using a finger-stick blood sample, allowing for targeted dietary recommendations to alleviate IBS symptoms [5] - Clinical studies have shown that patients using the inFoods IBS treatment diet experienced a greater than 30% reduction in abdominal pain compared to those on a placebo diet, indicating clinical significance [5]

BioHarvest Sciences Announces Uplisting to the Nasdaq Global MarketCommon Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024November 07, 2024 8:30 AM EST | Source: BioHarvest Sciences Inc.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC h ...